What is the recommended diagnostic workup for suspected cerebral amyloidosis in an older adult presenting with progressive cognitive decline, visual disturbances, or gait instability?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnostic Workup for Cerebral Amyloid Angiopathy

Begin with brain MRI including FLAIR, T2-weighted imaging (preferably susceptibility-weighted imaging/SWI), diffusion-weighted imaging, and contrast-enhanced T1-weighted or FLAIR sequences to identify hemorrhagic and non-hemorrhagic CAA markers, then apply the Boston criteria version 2.0 for diagnosis* 1.

Initial Clinical Assessment

Suspect CAA in patients over 50 years presenting with:

  • Hemorrhagic presentations: Spontaneous lobar intracerebral hemorrhage, transient focal neurological episodes
  • Cognitive presentations: Progressive cognitive decline (ranging from mild impairment to dementia)
  • Other manifestations: Visual disturbances, gait instability, seizures, or headaches

The clinical context matters significantly—CAA-related inflammation (CAA-ri) typically presents more acutely with subacute encephalopathy, seizures, and headaches, while typical CAA presents more insidiously 1.

MRI Protocol (Strong Recommendation)

Required sequences 1:

  • FLAIR: Identifies white matter hyperintensities and asymmetric confluent hyperintensities (in CAA-ri)
  • T2-weighted imaging* (SWI preferred): Detects cerebral microbleeds (CMBs), cortical superficial siderosis (cSS), and lobar hemorrhages
  • Diffusion-weighted imaging: Excludes acute ischemia and identifies cortical microinfarctions
  • Contrast-enhanced T1 or FLAIR: Detects leptomeningeal enhancement (particularly in CAA-ri)

Key MRI Findings to Document

Hemorrhagic Markers:

  • Lobar cerebral microbleeds (strictly lobar distribution)
  • Cortical superficial siderosis (focal or disseminated)
  • Lobar intracerebral hemorrhage
  • Cortical subarachnoid hemorrhage

Non-Hemorrhagic Markers:

  • Severe centrum semiovale perivascular spaces (CSO-PVS)
  • White matter hyperintensities in multispot pattern
  • Cortical microinfarctions (visible on double inversion recovery or 3D-FLAIR at 3T)

Applying Boston Criteria Version 2.0

The 2022 Boston criteria v2.0 2 significantly improves sensitivity (74.5-92.5%) while maintaining high specificity (81.5-95%) compared to older versions. Recent data shows that in Alzheimer's disease patients, v2.0 identifies probable CAA in 26.7% versus only 9.3% with the original criteria 3.

Probable CAA requires EITHER:

  • ≥2 strictly lobar hemorrhagic lesions (ICH, CMBs, or cSS foci), OR
  • ≥1 strictly lobar hemorrhagic lesion PLUS ≥1 white matter characteristic (severe CSO-PVS or multispot WMH pattern)

Possible CAA:

  • Single lobar hemorrhagic lesion or white matter characteristics alone

This represents a critical update—the inclusion of non-hemorrhagic markers substantially increases diagnostic sensitivity, particularly important in early disease stages where hemorrhagic markers may be minimal 2, 3.

Additional Diagnostic Testing

When CAA-Related Inflammation is Suspected

If the patient presents with subacute encephalopathy, seizures, headaches, or MRI shows asymmetric confluent FLAIR hyperintensities or leptomeningeal enhancement 1:

  1. CSF analysis (weak recommendation but clinically important): Exclude infectious or other autoimmune etiologies
  2. Consider brain biopsy if diagnostic uncertainty persists after non-invasive testing or if there's poor response to first-line immunotherapy (strong recommendation) 1

Genetic Testing Considerations

While not part of routine workup, APOE genotyping may provide prognostic information—APOE ε2 homozygosity is associated with more aggressive hemorrhagic progression and worse outcomes 4.

Histopathological Confirmation

Brain biopsy or surgical tissue sampling provides definitive diagnosis 1:

  • If lobar hematoma evacuation is performed, strongly recommended to obtain tissue including brain parenchyma and/or leptomeninges (not just clot material)
  • Vascular amyloid deposition is best visualized in cortical and leptomeningeal vessels
  • Consider biopsy in atypical presentations or when diagnosis remains uncertain despite comprehensive workup

Common Pitfalls to Avoid

  1. Don't rely solely on hemorrhagic markers: White matter findings (severe CSO-PVS, multispot WMH) are actually more common than hemorrhagic markers in early CAA—55% vs 16% in one AD cohort 3

  2. Don't miss CAA-ri: This inflammatory variant requires urgent immunosuppression but can be mistaken for other conditions. Look specifically for asymmetric confluent FLAIR hyperintensities and leptomeningeal enhancement 1

  3. Don't use inadequate MRI sequences: Standard T2-weighted imaging misses many microbleeds—susceptibility-weighted imaging is superior 5

  4. Don't confuse with deep hemorrhages: CAA produces strictly lobar hemorrhages; deep or infratentorial hemorrhages suggest hypertensive vasculopathy instead

  5. Recognize ARIA in patients on anti-amyloid therapy: Amyloid-related imaging abnormalities (ARIA-E and ARIA-H) mimic CAA-ri but occur in the context of lecanemab or donanemab treatment 1, 6

Functional Imaging (Optional)

Brain perfusion SPECT may show hypoperfusion in cortical areas affected by hemorrhagic lesions, particularly useful for assessing functional impact in cases with extensive cSS 4, though this is not part of standard diagnostic workup.

References

Related Questions

What are the diagnostic and management approaches for cerebral amyloid angiopathy?
In an elderly patient with cerebral amyloid angiopathy, how should cardiovascular risk and cardiac comorbidities be managed, including anticoagulation, antiplatelet therapy, blood pressure control, dyslipidemia treatment, and screening for cardiac amyloid involvement?
What is the recommended treatment approach for an elderly patient with cerebral amyloid angiopathy, likely with cognitive decline and vascular risk factors such as hypertension, diabetes, and hyperlipidemia?
What are the treatment options for cerebral amyloid angiopathy (CAA)?
How should I manage a patient with cerebral amyloid angiopathy presenting with transient neurological episodes (amyloid spells)?
What is the name of the hernia in which a segment of the large bowel protrudes into the hernia sac?
What is the appropriate evaluation and management for a patient who develops fever one week after coronary stent placement?
When should rivaroxaban be discontinued prior to surgery?
Why should inhaled corticosteroids be withdrawn during an acute pneumonia episode in a patient with chronic obstructive pulmonary disease?
How should a 15 mL vial of potassium phosphate containing 45 mmol of phosphate and 66 mmol of potassium be diluted for intravenous administration?
What are non‑NSAID alternatives for pain management in a patient on Sevikar HCT (olmesartan/amlodipine/hydrochlorothiazide) with Achilles tendinopathy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.